Utility of PSMA-PET derived volumetric parameters in initial risk stratification and prediction of prostate cancer metastasis - a head-to-head comparison of the radiotracers 18F-PSMA-1007 and 68Ga-PSMA-11

被引:0
|
作者
Chandekar, Kunal Ramesh [1 ,4 ]
Satapathy, Swayamjeet [1 ,4 ]
Singh, Harmandeep [1 ]
Kumar, Rajender [1 ]
Kumar, Santosh [2 ]
Kakkar, Nandita [3 ]
Mittal, Bhagwant Rai [1 ]
Singh, Shrawan Kumar [2 ,5 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Nucl Med, Chandigarh 160012, India
[2] Post Grad Inst Med Educ & Res, Dept Urol, Chandigarh, India
[3] Post Grad Inst Med Educ & Res, Dept Histopathol, Chandigarh, India
[4] All India Inst Med Sci, Dept Nucl Med, New Delhi, India
[5] Fortis Hosp, Dept Urol, Mohali, India
关键词
F-18-PSMA-1007; Ga-68-PSMA-11; PET/computed tomography; prostate cancer; prostate; specific membrane antigen; volumetric parameters; VARIABILITY;
D O I
10.1097/MNM.0000000000001874
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: This study aimed to explore and compare the utility of baseline F-18-PSMA-1007 and Ga-68-PSMA-11 PET/computed tomography (CT) derived volumetric parameters in initial risk stratification and prediction of prostate cancer (PCa) metastasis. Methods: Forty treatment-naive, biopsy-proven intermediate-/high-risk PCa patients were prospectively recruited. Each patient underwent PET/CT with Ga-68-PSMA-11 and F-18-PSMA-1007 (within 2 weeks). The maximum and mean standardized uptake values (SUVmax and SUVmean) of primary tumor, prostate PSMA-tumor volume (PSMA-TVp), and prostate total lesion PSMA (TL-PSMAp) were measured. Results: PSMA-TVp and TL-PSMAp (with both radiotracers) mostly exhibited moderate-to-strong correlation with Gleason score, serum prostate-specific antigen level and clinical tumor stage (Spearman rho = 0.361-0.783, P-values <= 0.022). Primary tumor SUVmax values were similar across initial risk categories. PSMA-TVp and TL-PSMAp, however, were significantly higher in high-risk PCa compared to intermediate-risk PCa (P-values <= 0.001). Receiver operating characteristic (ROC) curve analysis revealed that F-PSMA-TVp, Ga-PSMA-TVp, F-TL-PSMAp, and Ga-TL-PSMAp (optimal cutoff values of 20.9, 23.4, 142.5, and 144.8, respectively) could effectively differentiate high-risk from intermediate-risk PCa [area under the ROC curve (AUCs) 0.859-0.898, P-values <0.001] with high sensitivity (similar to 68.8-75%) and excellent specificity (100%). PSMA-TVp and TL-PSMAp (with both radiotracers) could predict presence of regional and extraregional nodal metastasis (AUCs 0.703-0.801, P-values <= 0.03) with moderate sensitivity (similar to 47.8-70.6%) and excellent specificity (similar to 82.6-94.1%). Conclusion: Our results suggest that baseline PSMA-PET primary tumor volumetric parameters provide a noninvasive, objective, and accurate index for initial risk stratification and can predict presence of regional and extraregional nodal metastasis in PCa patients. Larger studies are warranted to evaluate their incremental role over conventional parameters. Copyright (c) 2024 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 50 条
  • [1] Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard
    Kuten, Jonathan
    Fahoum, Ibrahim
    Savin, Ziv
    Shamni, Ofer
    Gitstein, Gilad
    Hershkovitz, Dov
    Mabjeesh, Nicola J.
    Yossepowitch, Ofer
    Mishani, Eyal
    Even-Sapir, Einat
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (04) : 527 - 532
  • [2] Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies
    Huasong Huo
    Shurui Shen
    Ding He
    Bin Liu
    Fuwei Yang
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 16 - 24
  • [3] Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies
    Huo, Huasong
    Shen, Shurui
    He, Ding
    Liu, Bin
    Yang, Fuwei
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 16 - 24
  • [4] Comparison of 18F-PSMA-1007 PET/CT With 68Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer
    Chandekar, Kunal Ramesh
    Singh, Harmandeep
    Kumar, Rajender
    Kumar, Santosh
    Kakkar, Nandita
    Mittal, Bhagwant Rai
    Singh, Shrawan Kumar
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (01) : E1 - E8
  • [5] Serial 18F-PSMA-1007 PET/CT imaging: A comparative study with 68Ga-PSMA-11
    Sharma, P.
    Watts, A.
    Singh, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S114 - S115
  • [6] Comparative analysis of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer restaging PET/CT: differences and similarities
    Lavelli, V.
    Ferrari, C.
    Pisani, A. R.
    Battisti, C.
    Palumbo, C.
    Merenda, N. C.
    Rubini, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S535 - S536
  • [7] Comparison of 18F-PSMA-1007 PET/CT with 68Ga-PSMA-11 PET/CT for initial staging in intermediate and high-risk prostate cancer - A Pilot Study
    Chandekar, Kunal
    Singh, Harmandeep
    Kumar, Rajender
    Bhattacharya, Anish
    Mittal, Bhagwant
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [8] Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI
    Zhang, Yan-Nan
    Lu, Zhen-Guo
    Wang, Shuai-Dong
    Lu, Xin
    Zhu, Lei-Lei
    Yang, Xu
    Fu, Li-Ping
    Zhao, Jun
    Wang, Hai-Feng
    Xiang, Zuo-Lin
    CANCER IMAGING, 2022, 22 (01)
  • [9] Gross tumor volume delineation in primary prostate cancer on 18F-PSMA-1007 PET/MRI and 68Ga-PSMA-11 PET/MRI
    Yan-Nan Zhang
    Zhen-Guo Lu
    Shuai-Dong Wang
    Xin Lu
    Lei-Lei Zhu
    Xu Yang
    Li-Ping Fu
    Jun Zhao
    Hai-Feng Wang
    Zuo-Lin Xiang
    Cancer Imaging, 22
  • [10] Optimal 68Ga-PSMA-11 and 18F-PSMA-1007 PET window levelling for gross tumour volume delineation in primary prostate cancer
    Goffin, K.
    Draulans, C.
    De Roover, R.
    van der Heide, U. A.
    Kerkmeijer, L.
    Smeenk, R. J.
    Pos, F.
    Vogel, W. V.
    Nagarajah, J.
    Janssen, M.
    Isebaert, S.
    Maes, F.
    Mai, C.
    Oyen, R.
    Joniau, S.
    Kunze-Busch, M.
    Haustermans, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S404 - S405